bioAffinity Technologies announces validation study with Brooke Army Medical Center for CyPath Lung test

bioAffinity Technologies, Inc.

Study with BAMC to validate CyPath Lung on sputum obtained by tracheal/bronchial suctioning for early lung cancer detection.
Enrolling 30-50 patients; results expected by mid-2026.
Potential to expand sample collection options; currently patients collect sputum at home.
U.S. bronchoscopy procedures ~500,000 annually; market valued at $700-920M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.